FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4384697790> ?p ?o ?g. }

• W4384697790 abstract "Abstract While the nervous system has reciprocal interactions with both cancer and the immune system, little is known about the potential role of tumor associated nerves (TANs) in modulating anti-tumoral immunity. Moreover, while peri-neural invasion is a well establish poor prognostic factor across cancer types, the mechanisms driving this clinical effect remain unknown. Here, we provide clinical and mechniastic association between TANs damage and resistance to anti-PD-1 therapy. Using electron microscopy, electrical conduction studies, and tumor samples of cutaneous squamous cell carcinoma (cSCC) patients, we showed that cancer cells can destroy myelin sheath and induce TANs degeneration. Multi-omics and spatial analyses of tumor samples from cSCC patients who underwent neoadjuvant anti-PD-1 therapy demonstrated that anti-PD-1 non-responders had higher rates of peri-neural invasion, TANs damage and degeneration compared to responders, both at baseline and following neoadjuvant treatment. Tumors from non-responders were also characterized by a sustained signaling of interferon type I (IFN-I) – known to both propagate nerve degeneration and to dampen anti-tumoral immunity. Peri-neural niches of non-responders were characterized by higher immune activity compared to responders, including immune-suppressive activity of M2 macrophages, and T regulatory cells. This tumor promoting inflammation expanded to the rest of the tumor microenvironment in non-responders. Anti-PD-1 efficacy was dampened by inducing nerve damage prior to treatment administration in a murine model. In contrast, anti-PD-1 efficacy was enhanced by denervation and by interleukin-6 blockade. These findings suggested a potential novel anti-PD-1 resistance drived by TANs damage and inflammation. This resistance mechanism is targetable and may have therapeutic implications in other neurotropic cancers with poor response to anti-PD-1 therapy such as pancreatic, prostate, and breast cancers." @default.
• W4384697790 created "2023-07-20" @default.
• W4384697790 creator A5004685117 @default.
• W4384697790 creator A5007005578 @default.
• W4384697790 creator A5007020035 @default.
• W4384697790 creator A5008665039 @default.
• W4384697790 creator A5012111063 @default.
• W4384697790 creator A5013938672 @default.
• W4384697790 creator A5013941498 @default.
• W4384697790 creator A5013945697 @default.
• W4384697790 creator A5015122587 @default.
• W4384697790 creator A5015713295 @default.
• W4384697790 creator A5017436055 @default.
• W4384697790 creator A5020811172 @default.
• W4384697790 creator A5021359372 @default.
• W4384697790 creator A5026642238 @default.
• W4384697790 creator A5029345745 @default.
• W4384697790 creator A5031977448 @default.
• W4384697790 creator A5034714627 @default.
• W4384697790 creator A5035427219 @default.
• W4384697790 creator A5038554310 @default.
• W4384697790 creator A5047117233 @default.
• W4384697790 creator A5048327749 @default.
• W4384697790 creator A5050916441 @default.
• W4384697790 creator A5056577711 @default.
• W4384697790 creator A5057320091 @default.
• W4384697790 creator A5058902095 @default.
• W4384697790 creator A5068440044 @default.
• W4384697790 creator A5068859775 @default.
• W4384697790 creator A5069469851 @default.
• W4384697790 creator A5071033599 @default.
• W4384697790 creator A5071523175 @default.
• W4384697790 creator A5073502048 @default.
• W4384697790 creator A5074897739 @default.
• W4384697790 creator A5076198642 @default.
• W4384697790 creator A5077499798 @default.
• W4384697790 creator A5077700916 @default.
• W4384697790 creator A5078144632 @default.
• W4384697790 creator A5078803444 @default.
• W4384697790 creator A5080934130 @default.
• W4384697790 creator A5084628235 @default.
• W4384697790 date "2023-07-18" @default.
• W4384697790 modified "2023-10-18" @default.
• W4384697790 title "Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by IL-6 blockade" @default.
• W4384697790 cites W1532654778 @default.
• W4384697790 cites W1611944043 @default.
• W4384697790 cites W1952419792 @default.
• W4384697790 cites W1979049647 @default.
• W4384697790 cites W2000177767 @default.
• W4384697790 cites W2018110972 @default.
• W4384697790 cites W2039123767 @default.
• W4384697790 cites W2049959255 @default.
• W4384697790 cites W2057388449 @default.
• W4384697790 cites W2101173536 @default.
• W4384697790 cites W2111964682 @default.
• W4384697790 cites W2122830702 @default.
• W4384697790 cites W2124770605 @default.
• W4384697790 cites W2126974532 @default.
• W4384697790 cites W2130418945 @default.
• W4384697790 cites W2138275768 @default.
• W4384697790 cites W2148214085 @default.
• W4384697790 cites W2151399165 @default.
• W4384697790 cites W2151596048 @default.
• W4384697790 cites W2152897456 @default.
• W4384697790 cites W2346820190 @default.
• W4384697790 cites W2395031718 @default.
• W4384697790 cites W2401455386 @default.
• W4384697790 cites W2469842653 @default.
• W4384697790 cites W2558219863 @default.
• W4384697790 cites W2560367415 @default.
• W4384697790 cites W2572191542 @default.
• W4384697790 cites W2573152477 @default.
• W4384697790 cites W2587048937 @default.
• W4384697790 cites W2613155082 @default.
• W4384697790 cites W2625298747 @default.
• W4384697790 cites W2730836138 @default.
• W4384697790 cites W2796030496 @default.
• W4384697790 cites W2798160602 @default.
• W4384697790 cites W2810879984 @default.
• W4384697790 cites W2888581124 @default.
• W4384697790 cites W2890229155 @default.
• W4384697790 cites W2890875511 @default.
• W4384697790 cites W2905817704 @default.
• W4384697790 cites W2905952738 @default.
• W4384697790 cites W2910310961 @default.
• W4384697790 cites W2912834287 @default.
• W4384697790 cites W2913383852 @default.
• W4384697790 cites W2916647762 @default.
• W4384697790 cites W2932264222 @default.
• W4384697790 cites W2946891991 @default.
• W4384697790 cites W2948475148 @default.
• W4384697790 cites W2956701599 @default.
• W4384697790 cites W2967398918 @default.
• W4384697790 cites W2972096813 @default.
• W4384697790 cites W2982276024 @default.
• W4384697790 cites W2999300346 @default.
• W4384697790 cites W3005376436 @default.
• W4384697790 cites W3005855303 @default.
• W4384697790 cites W3013045025 @default.
• W4384697790 cites W3017089772 @default.

• next